AstraZeneca (LON:AZN) Receives Hold Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of AstraZeneca (LON:AZN) in a report released on Tuesday morning, Marketbeat.com reports. The brokerage currently has a £105 ($129.69) price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the stock. JPMorgan Chase & Co. reissued an overweight rating on shares of AstraZeneca in a research report on Thursday, April 4th. Berenberg Bank reaffirmed a buy rating on shares of AstraZeneca in a research report on Wednesday, March 13th. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research report on Monday, April 15th. UBS Group dropped their price target on shares of AstraZeneca from £107 ($132.16) to GBX 9,900 ($122.28) and set a sell rating on the stock in a research report on Monday, February 12th. Finally, Barclays reaffirmed an overweight rating and issued a £125 ($154.40) price target on shares of AstraZeneca in a research report on Monday, April 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of £116.86 ($144.34).

AstraZeneca Price Performance

AZN stock opened at £113.72 ($140.46) on Tuesday. The stock has a market capitalization of £176.27 billion, a PE ratio of 3,718.81, a price-to-earnings-growth ratio of 0.89 and a beta of 0.19. The company’s 50-day moving average is £104.63 and its 200-day moving average is £104.27. The company has a debt-to-equity ratio of 75.70, a current ratio of 0.82 and a quick ratio of 0.59. AstraZeneca has a 1 year low of GBX 9,461 ($116.86) and a 1 year high of £123.48 ($152.52).

AstraZeneca Increases Dividend

The company also recently announced a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were given a dividend of GBX 156 ($1.93) per share. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a dividend yield of 1.49%. This is a boost from AstraZeneca’s previous dividend of $71.80. AstraZeneca’s dividend payout ratio (DPR) is currently 7,524.75%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.